In 2023, the US FDA approved Beremagene Geperpavec for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a monogenic disease caused by mutations in COL7A1 [219,220]. The gene discussed is COL7A1; the disease is recessive dystrophic epidermolysis bullosa.